Special Issue

Plant Medicines: New Therapeutic Uses

Message from the Guest Editor

Clinical trials focused on plant-derived medicines are being conducted in China, India, Europe and other places. These trials seek to prove the efficacy, safety and environmental sustainability of plant medicines. The advantage of plant medicines is that the human body has been exposed to them for thousands of years and may have adapted to them. Many of these medicines are useful when therapies are limited by resistance and toxicity problems. However, plant medicines should be tested in clinical trials to prove their purity, efficacy and safety. The chemistry and mechanisms of action underlying these medicines should be reported. They should also be examined for environmental sustainability. Plant species that are uncommon should be grown in farms to make their use sustainable.

Guest Editor

Prof. Dr. James David Adams

School of Pharmacy, University of Southern California, 1985 Zonal Avenue, Los Angeles, CA 90089, USA

Deadline for manuscript submissions

closed (30 November 2024)



Medicines

an Open Access Journal by MDPI

Indexed in PubMed



mdpi.com/si/198754

Medicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
medicines@mdpi.com

mdpi.com/journal/ medicines





Medicines

an Open Access Journal by MDPI

Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Hiroshi Sakagami

Meikai University Research Institute of Odontology (M-RIO), 1-1 Keyakidai, Sakado, Saitama 350-0283, Japan

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within PubMed, PMC, CAPlus / SciFinder, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 45 days after submission; acceptance to publication is undertaken in 5.7 days (median values for papers published in this journal in the first half of 2025).

